

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

-----  
FORM 8-K  
-----

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):  
January 10, 2007

USANA HEALTH SCIENCES, INC.  
(Exact name of registrant as specified in its charter)

Commission File No. 0-21116

Utah  
(State or other jurisdiction  
of incorporation)

87-0500306  
(IRS Employer Identification  
Number)

3838 West Parkway Boulevard  
Salt Lake City, Utah 84120  
(Address of principal executive offices, Zip Code)

Registrant's telephone number, including area code: (801) 954-7100

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On January 10, 2007, USANA Health Sciences, Inc. issued a press release announcing its preliminary financial results for the fourth quarter ended December 30, 2006. The release also announced that the Company plans to release its final fourth quarter and full year 2006 results on February 6, 2007. A copy of the press release is furnished herewith as Exhibit 99 to this Current Report on Form 8-K and is incorporated herein by reference. The company will also post this document on its corporate website, [www.usanahealthsciences.com](http://www.usanahealthsciences.com).

The information in this Item 2.02 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing

is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.

#### Item 8.01 Other Events

The Company also announced in the January 10, 2007 press release that it has commenced operations in Malaysia and began accepting applications and processing orders there on January 8, 2007.

Additionally, the Company announced that it will make an immaterial reclassification to its consolidated financial statements beginning with the fourth quarter 2006. This reclassification will not affect reported operating earnings, net earnings, or earnings per share. However, this reclassification will reduce net sales by approximately 1.5%, offset by a corresponding reduction in Associate incentive expense. The Company provided historical financial tables that include both pre and post-reclassification data for the quarterly periods for fiscal years 2004, 2005, and for the nine months ended September 30, 2006.

#### Item 9.01 Financial Statements and Exhibits.

##### (d) Exhibits

Exhibit 99 Press release issued by USANA Health Sciences, Inc. dated January 10, 2007 (furnished herewith).

2

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

USANA HEALTH SCIENCES, INC.

By: /s/ Gilbert A. Fuller

-----  
Gilbert A. Fuller,  
Chief Financial Officer

Date: January 10, 2007

3

USANA Provides Preliminary Fourth Quarter 2006 Results  
Record Fourth Quarter Net Sales and EPS to Exceed Guidance  
Company Begins Operations in Malaysia  
Minor Reclassification Made to Historical Revenue and Expense Items

SALT LAKE CITY--(BUSINESS WIRE)--Jan. 10, 2007--USANA Health Sciences, Inc. (NASDAQ:USNA) today provided preliminary financial results for its fourth quarter ended December 30, 2006. The company currently expects net sales for this period to be approximately \$101 million, before the reclassification as described below. This exceeds management's prior guidance of \$98 million to \$100 million. Net sales after the reclassification are expected to be approximately \$99.5 million, which represents the 18th consecutive quarter of record net sales. Earnings per share for the fourth quarter are expected to exceed management's previously announced guidance of \$0.56 to \$0.58. The company now anticipates that earnings per share will be in the range of \$0.58 to \$0.60 and are not affected by the reclassification as described below.

The company also announced today that it has commenced operations in Malaysia, USANA's 13th global market. The company began accepting new Associate applications and processing orders for this market on Monday, January 8, 2007.

"We are pleased that we have finished out 2006 with such strong results, which reflect the hard work and dedication of our Associates as well as the market's continued enthusiasm for our science-based products," said Dave Wentz, president of USANA. "Malaysia, one of the top 15 direct selling markets globally, should provide us with additional growth opportunities."

#### Revenue Reclassification

The company also announced today that it will make an immaterial reclassification to its consolidated financial statements beginning with the fourth quarter of 2006. This reclassification will not affect reported operating earnings, net earnings, or earnings per share. However, this reclassification will reduce net sales by approximately 1.5%, offset by a corresponding reduction in Associate incentive expense. This reclassification will be reflected in the fourth quarter earnings press release that will be issued in early February 2007.

Previously the company reported a component of its Associate compensation plan as an Associate incentive expense. Now, however, the company will reclassify that component as a sales discount. To facilitate comparison of the company's prior quarters, as well as comparison of that data with the company's past projections, the company has included in this press release historical financial tables that include both pre- and post-reclassification data. Quarterly data has been provided for fiscal years 2004, 2005, and for the nine-month period ended September 30, 2006.

#### Updated 2006 Guidance

Giving effect to the reclassification mentioned above, management now anticipates net sales for the full year 2006 to be approximately \$374 million. Because the reclassification will not affect earnings per share, management expects earnings per share for the full year 2006 to be in the range of \$2.18 to \$2.20, which is above the guidance range that was provided on October 17, 2006.

USANA plans to issue a press release for its final fourth quarter and full year 2006 results on February 6, 2007, which will incorporate the above noted reclassification. Executives will hold a conference call with investors on February 7, 2007 to discuss these results.

#### About USANA

USANA develops and manufactures high quality nutritionals, personal care, and weight management products that are sold directly to Preferred Customers and Associates throughout the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Netherlands, and the United Kingdom. More information on USANA can be found at <http://www.usanahealthsciences.com>.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including reliance upon our network of independent Associates, the governmental regulation of our products, manufacturing and marketing risks, and risks associated with our international expansion. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

USANA Health Sciences, Inc.  
Consolidated Statements of Earnings  
(In thousands, except per share data)  
(unaudited)

Quarter Ended

-----  
3-Apr-04 3-Jul-04 2-Oct-04 1-Jan-05 2-Apr-05  
-----

As Reclassified

Net sales	\$61,030	\$66,431	\$67,792	\$74,098	\$75,527
Cost of sales	15,058	16,195	16,732	18,837	18,010
Gross profit	45,972	50,236	51,060	55,261	57,517
Operating expenses					
Associate incentives	22,867	24,741	25,329	28,023	28,499
Selling, general and administrative	13,262	13,656	13,141	14,633	14,849
Research and development	578	607	450	396	599
Earnings from operations	9,265	11,232	12,140	12,209	13,570
Other income	149	(1)	(513)	598	165
Earnings before income taxes	9,414	11,231	11,627	12,807	13,735
Income taxes	3,201	3,818	3,631	3,652	4,807
NET EARNINGS	\$ 6,213	\$ 7,413	\$ 7,996	\$ 9,155	\$ 8,928

Earnings per share - diluted \$ 0.30 \$ 0.36 \$ 0.39 \$ 0.46 \$ 0.45

Weighted average shares outstanding - diluted 20,853 20,523 20,296 19,990 19,971

As Reported

Net sales	\$61,775	\$67,246	\$68,673	\$75,130	\$76,578
Cost of sales	15,058	16,195	16,732	18,837	18,010
Gross profit	46,717	51,051	51,941	56,293	58,568
Operating expenses					
Associate incentives	23,612	25,556	26,210	29,055	29,550
Selling, general and administrative	13,262	13,656	13,141	14,633	14,849

Research and development	578	607	450	396	599
-----					
Earnings from operations	9,265	11,232	12,140	12,209	13,570
Other income	149	(1)	(513)	598	165
-----					
Earnings before income taxes	9,414	11,231	11,627	12,807	13,735
Income taxes	3,201	3,818	3,631	3,652	4,807
-----					
NET EARNINGS	\$ 6,213	\$ 7,413	\$ 7,996	\$ 9,155	\$ 8,928
=====					

Earnings per share - diluted	\$ 0.30	\$ 0.36	\$ 0.39	\$ 0.46	\$ 0.45
=====					

Weighted average shares outstanding - diluted	20,853	20,523	20,296	19,990	19,971
=====					

Quarter Ended

-----  
2-Jul-05 1-Oct-05 31-Dec-05 1-Apr-06 1-Jul-06 30-Sep-06  
-----

As Reclassified

Net sales	\$80,878	\$81,038	\$85,646	\$88,229	\$92,482	\$93,698
Cost of sales	19,499	19,760	20,747	21,338	22,276	22,188
-----						

Gross profit	61,379	61,278	64,899	66,891	70,206	71,510
--------------	--------	--------	--------	--------	--------	--------

Operating expenses

Associate incentives	30,774	31,358	33,414	34,006	36,025	36,994
Selling, general and administrative	15,168	14,756	15,553	17,626	17,991	17,898
Research and development	689	551	500	732	830	881
-----						

Earnings from operations	14,748	14,613	15,432	14,527	15,360	15,737
--------------------------	--------	--------	--------	--------	--------	--------

Other income	(67)	172	217	295	336	68
-----						

Earnings before income taxes	14,681	14,785	15,649	14,822	15,696	15,805
------------------------------	--------	--------	--------	--------	--------	--------

Income taxes	5,138	4,743	5,168	5,262	5,352	5,582
-----						

NET EARNINGS	\$ 9,543	\$10,042	\$10,481	\$ 9,560	\$10,344	\$10,223
=====						

Earnings per share - diluted

\$ 0.48	\$ 0.51	\$ 0.54	\$ 0.50	\$ 0.55	\$ 0.55
=====					

Weighted average shares outstanding - diluted	19,821	19,755	19,336	19,228	18,777	18,486
---	--------	--------	--------	--------	--------	--------

---

As Reported

Net sales	\$82,015	\$82,225	\$86,924	\$89,651	\$93,911	\$95,187
Cost of sales	19,499	19,760	20,747	21,338	22,276	22,188

Gross profit	62,516	62,465	66,177	68,313	71,635	72,999
-----------------	--------	--------	--------	--------	--------	--------

Operating expenses						
Associate incentives	31,911	32,545	34,692	35,428	37,454	38,483
Selling, general and admini- strative	15,168	14,756	15,553	17,626	17,991	17,898
Research and development	689	551	500	732	830	881

Earnings from operations	14,748	14,613	15,432	14,527	15,360	15,737
--------------------------------	--------	--------	--------	--------	--------	--------

Other income	(67)	172	217	295	336	68
--------------	------	-----	-----	-----	-----	----

Earnings before income taxes	14,681	14,785	15,649	14,822	15,696	15,805
---------------------------------------	--------	--------	--------	--------	--------	--------

Income taxes	5,138	4,743	5,168	5,262	5,352	5,582
--------------	-------	-------	-------	-------	-------	-------

NET EARNINGS	\$ 9,543	\$10,042	\$10,481	\$ 9,560	\$10,344	\$10,223
--------------	----------	----------	----------	----------	----------	----------

---

Earnings per share - diluted	\$ 0.48	\$ 0.51	\$ 0.54	\$ 0.50	\$ 0.55	\$ 0.55
------------------------------------	---------	---------	---------	---------	---------	---------

---

Weighted average shares outstanding - diluted	19,821	19,755	19,336	19,228	18,777	18,486
---	--------	--------	--------	--------	--------	--------

---

USANA Health Sciences, Inc.  
Sales by Segment and Region  
(in thousands)  
(unaudited)

Quarter Ended

3-Apr-04 3-Jul-04 2-Oct-04 1-Jan-05 2-Apr-05 2-Jul-05

---

As Reclassified  
Region

North America						
United States	\$26,771	\$27,485	\$28,430	\$29,465	\$30,806	\$32,637
Canada	12,269	12,206	12,392	14,933	14,638	15,053

Mexico 747 2,209 2,255 3,047 3,174 3,889

-----  
North America

Total 39,787 41,900 43,077 47,445 48,618 51,579

Pacific Rim

Australia-New

Zealand 8,164 8,350 8,933 9,740 10,491 11,084

Hong Kong 2,407 2,670 2,765 2,977 2,938 3,263

Japan 2,196 2,155 2,330 2,439 2,465 2,577

Taiwan 3,698 3,865 3,866 4,432 5,019 5,337

South Korea 1,261 1,793 1,354 1,268 1,015 1,292

Singapore 1,983 2,578 2,638 2,969 3,052 3,543

-----  
Pacific Rim

Total 19,709 21,411 21,886 23,825 24,980 27,096

-----  
Segment Total 59,496 63,311 64,963 71,270 73,598 78,675

Contract

Manufacturing 1,534 3,120 2,829 2,828 1,929 2,203

-----  
Consolidated \$61,030 \$66,431 \$67,792 \$74,098 \$75,527 \$80,878

As Reported

Region

-----  
North America

United States \$27,101 \$27,821 \$28,827 \$29,830 \$31,203 \$33,067

Canada 12,437 12,378 12,553 15,184 14,862 15,287

Mexico 748 2,216 2,268 3,064 3,193 3,910

-----  
North America

Total 40,286 42,415 43,648 48,078 49,258 52,264

Pacific Rim

Australia-New

Zealand 8,276 8,471 9,056 9,881 10,644 11,241

Hong Kong 2,457 2,750 2,837 3,073 3,040 3,377

Japan 2,216 2,176 2,356 2,470 2,498 2,620

Taiwan 3,729 3,898 3,903 4,479 5,064 5,381

South Korea 1,270 1,804 1,366 1,302 1,045 1,323

Singapore 2,007 2,612 2,678 3,019 3,100 3,606

-----  
Pacific Rim

Total 19,955 21,711 22,196 24,224 25,391 27,548

-----  
Segment Total 60,241 64,126 65,844 72,302 74,649 79,812

Contract

Manufacturing 1,534 3,120 2,829 2,828 1,929 2,203

-----  
Consolidated \$61,775 \$67,246 \$68,673 \$75,130 \$76,578 \$82,015

Quarter Ended

-----  
1-Oct-05 31-Dec-05 1-Apr-06 1-Jul-06 30-Sep-06

As Reclassified

Region

-----  
North America

United States \$34,636 \$36,148 \$38,468 \$39,250 \$39,425

Canada 15,014 16,547 16,701 17,721 16,574

Mexico 3,424 3,479 4,053 4,323 4,503

North America Total 53,074 56,174 59,222 61,294 60,502

Pacific Rim

Australia-New Zealand 11,180 11,956 11,100 12,104 12,297

Hong Kong 2,889 3,127 3,064 3,376 4,533

Japan 2,526 2,605 2,399 2,379 2,357

Taiwan 4,852 4,860 4,939 4,978 5,509

South Korea 1,218 1,225 1,180 1,704 2,117

Singapore 3,624 3,370 3,427 3,813 4,603

Pacific Rim Total 26,289 27,143 26,109 28,354 31,416

Segment Total 79,363 83,317 85,331 89,648 91,918

Contract Manufacturing 1,675 2,329 2,898 2,834 1,780

Consolidated \$81,038 \$85,646 \$88,229 \$92,482 \$93,698

As Reported

Region

North America

United States \$35,181 \$36,672 \$39,057 \$39,818 \$40,015

Canada 15,231 16,813 16,979 18,010 16,814

Mexico 3,449 3,508 4,098 4,373 4,555

North America Total 53,861 56,993 60,134 62,201 61,384

Pacific Rim

Australia-New Zealand 11,341 12,141 11,274 12,291 12,488

Hong Kong 2,971 3,234 3,176 3,480 4,643

Japan 2,562 2,643 2,432 2,417 2,390

Taiwan 4,885 4,895 4,981 5,034 5,587

South Korea 1,250 1,264 1,216 1,762 2,201

Singapore 3,680 3,425 3,540 3,892 4,714

Pacific Rim Total 26,689 27,602 26,619 28,876 32,023

Segment Total 80,550 84,595 86,753 91,077 93,407

Contract Manufacturing 1,675 2,329 2,898 2,834 1,780

Consolidated \$82,225 \$86,924 \$89,651 \$93,911 \$95,187

CONTACT: USANA Health Sciences, Inc.

Riley Timmer, Investor Relations, (801) 954-7100

investor.relations@us.usana.com